Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPOP-guided chemotherapy in recurrent high grade astrocytic glioma
NCT05532397Recruiting
- Sponsor
- National University Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in astrocytoma, sponsored by National University Hospital. Primary endpoint: Six-month progression-free survival at 6 months. Started Feb 2023; status: recruiting.
02
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT05532397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532397.